Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

121.11USD
22 Jul 2014
Price Change (% chg)

$2.08 (+1.75%)
Prev Close
$119.03
Open
$119.59
Day's High
$121.25
Day's Low
$119.38
Volume
1,032,539
Avg. Vol
1,167,527
52-wk High
$128.96
52-wk Low
$103.31

AMGN.OQ

Chart for AMGN.OQ

About

Amgen Inc. is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics. Its medicines help millions of patients in the fight against cancer, kidney disease, rheumatoid arthritis (RA), bone disease, and other serious illnesses. On December 10, 2012, the Company acquired all of the... (more)

Overall

Beta: 0.53
Market Cap (Mil.): $91,682.89
Shares Outstanding (Mil.): 757.02
Dividend: 0.61
Yield (%): 2.01

Financials

  AMGN.OQ Industry Sector
P/E (TTM): 19.66 35.59 35.92
EPS (TTM): 6.16 -- --
ROI: 8.96 18.98 18.26
ROE: 22.35 19.75 19.14
Search Stocks

Bind Therapeutics ends cancer drug partnership with Amgen

- Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.

02 Jul 2014

Bind Therapeutics ends cancer drug partnership with Amgen

July 2 - Drug developer Bind Therapeutics said it ended a partnership with Amgen Inc to develop targeted cancer therapy due to unsatisfactory results.

02 Jul 2014

Amgen psoriatic arthritis drug maintains efficacy after 1 yr -study

June 11 - A drug being developed by Amgen Inc for psoriatic arthritis demonstrated sustained effectiveness after a year of treatment with no new safety concerns, according to data from a midstage trial.

11 Jun 2014

Amgen names former 3M CFO Meline as finance chief

June 9 - Amgen Inc, the world's largest biotechnology company, on Monday named manufacturing and auto industry veteran David Meline as chief financial officer.

09 Jun 2014

Insurers scrutinize drug costs after $84,000 Sovaldi surprise

NEW YORK/LOS ANGELES - Shocked by the rapid adoption of a new $84,000 hepatitis C treatment, U.S. health insurers are trying to make sure they aren’t blindsided by other drugs being developed and are looking for ways to limit their use from the day they are launched.

28 May 2014

CORRECTED-INSIGHT-RPT-Insurers scrutinize drug costs after $84,000 Sovaldi surprise

(Corrects to Reimbursement Intelligence from Intelligence Reimbursement, to Whang as co-president from president, to Steve Miller from Stuart Miller)

28 May 2014

CORRECTED-INSIGHT-Insurers scrutinize drug costs after $84,000 Sovaldi surprise

(Corrects to Reimbursement Intelligence from Intelligence Reimbursement, to Whang as co-president from president, to Steve Miller from Stuart Miller)

28 May 2014

Qiagen wins U.S. approval for test to accompany Amgen cancer drug

FRANKFURT - U.S. health regulators on Friday approved Qiagen NV's gene-testing kit to identify those colorectal cancer patients most likely to benefit from Amgen Inc's drug, Vectibix, Qiagen said.

23 May 2014

Qiagen wins U.S. approval for test to accompany Amgen cancer drug

FRANKFURT, May 23 - U.S. health regulators on Friday approved Qiagen NV's gene-testing kit to identify those colorectal cancer patients most likely to benefit from Amgen Inc's drug, Vectibix, Qiagen said.

23 May 2014

Fitch Rates Amgen's Unsecured Debt Issuance 'BBB'

(The following statement was released by the rating agency) CHICAGO, May 19 (Fitch) Fitch Ratings has assigned a 'BBB' rating to Amgen Inc.'s (Amgen) proposed $4.5 billion unsecured notes offering. Fitch expects Amgen to use the net proceeds for general corporate purposes, including funding the repayment of preferred shares under its Master Repurchase Agreement or outstanding term loan borrowings, and pre-funding a portion of its outstanding 1.875% unsecured notes and 4.85% unsecured notes

19 May 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks